13-Feb-2026
PRNewswire (Fri, 13-Feb 10:23 AM ET)
PRNewswire (Thu, 12-Feb 6:56 PM ET)
Globe Newswire (Tue, 3-Feb 8:13 PM ET)
Business Wire (Mon, 2-Feb 1:24 PM ET)
AQST’s FDA Roadblock Is Packaging, Not Product—Anaphylm’s Path Forward Looks Manageable
Market Chameleon (Mon, 2-Feb 5:29 AM ET)
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm
Globe Newswire (Mon, 2-Feb 7:00 AM ET)
PRNewswire (Sun, 25-Jan 8:24 PM ET)
Globe Newswire (Fri, 23-Jan 10:14 AM ET)
Aquestive Therapeutics Expands Leadership Team to Accelerate Anaphylm Launch and Pipeline Growth
Market Chameleon (Tue, 4-Nov 3:35 AM ET)
Aquestive’s New Patents Extend Anaphylm Protection to 2037—Could This Disrupt Epinephrine Delivery?
Market Chameleon (Thu, 9-Oct 7:59 AM ET)
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics trades on the NASDAQ stock market under the symbol AQST.
As of February 13, 2026, AQST stock price declined to $3.65 with 2,516,080 million shares trading.
AQST has a beta of 0.60, meaning it tends to be less sensitive to market movements. AQST has a correlation of 0.01 to the broad based SPY ETF.
AQST has a market cap of $445.31 million. This is considered a Small Cap stock.
Last quarter Aquestive Therapeutics reported $13 million in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-303,100 and missed earnings estimates by -$.02.
In the last 3 years, AQST traded as high as $7.55 and as low as $.72.
The top ETF exchange traded funds that AQST belongs to (by Net Assets): VTI, IWM, VXF, VTWO, XPH.
AQST has underperformed the market in the last year with a return of +5.2%, while the SPY ETF gained +13.0%. In the last 3 month period, AQST fell short of the market, returning -31.1%, while SPY returned +1.7%. However, in the most recent 2 weeks AQST has outperformed the stock market by returning +23.7%, while SPY returned -1.5%.
AQST support price is $3.56 and resistance is $3.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AQST shares will trade within this expected range on the day.
